Drugs / Recombinant glycosylated human interleukin-7
Recombinant glycosylated human interleukin-7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06523699 | Apr 2025 → Apr 2029 expected | plasma cell myeloma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant glycosylated human interleukin-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06523699 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant glycosylated human interleukin-7” NCT06523699 ↗ |